In order to submit a request for general meeting support for an Annual Meeting, the answers to the following questions must be “Yes”:

☐ Does the activity align with Pfizer’s Primary Areas of Interest? *(listed below)*

☐ Is the activity a live* annual program which serves as a platform for the exchange of new clinical and scientific information and reaches an international, national, regional or local audience?

*Live CME/CE activities are defined as any activity which incorporates the opportunity for live real-time learner interaction, such as live meetings and live webcasts/webinars*

☐ Is the activity an established part of your organization’s ongoing educational program? If not and it is a new activity, is it clearly based on an assessment of the educational needs of your target audience?

☐ Is the requested grant amount within the following parameters: $50,000 or less for an Annual Meeting with a national/international target audience; $25,000 or less for an Annual Meeting with a regional/local target audience?

<table>
<thead>
<tr>
<th>Application Cycle</th>
<th>To Submit Live Activity Must Start On or After</th>
<th>Decision Communicated By*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jan 1 - Feb 15</td>
<td>Apr 1</td>
<td>Mar 15</td>
</tr>
<tr>
<td>Mar 1 - Apr 15</td>
<td>July 1</td>
<td>May 31</td>
</tr>
<tr>
<td>June 1 - July 15</td>
<td>Oct 1</td>
<td>Aug 30</td>
</tr>
<tr>
<td>Sept 1 - Oct 15</td>
<td>Jan 1, 2020</td>
<td>Nov 29</td>
</tr>
</tbody>
</table>

If your activity is in..... Latest* Date to submit to Pfizer is....

| April, May or June 2019 | February 15 |
| July, August or September 2019 | April 15 |
| October, November or December 2019 | July 15 |
| January, February or March 2020 | October 15 |

*This is the latest date to submit. Your request will be reviewed if submitted in an earlier cycle.

All applications must be submitted online via the Global Medical Grants System. Please [click here](#) to access the system.

**Questions? Email** [GlobalMedicalGrants@pfizer.com](mailto:GlobalMedicalGrants@pfizer.com)  
Revised March 2019
PLEASE NOTE: The ‘GMGS listing’ indicates the relevant Primary Areas of Interest found in the application dropdown menu in the Global Medical Grants System (GMGS). Some areas may have multiple options or a slightly different wording than the headers listed here.

Acromegaly

GMGS listing: Endocrine – Acromegaly

Improve the knowledge base of health care providers, educators, and third party payers working in the area of acromegaly.

Antidote Therapies and Emergency Care

GMGS listing: Antidote Therapies and Emergency Care

• Improve healthcare providers and policy makers understanding of antidote therapies and availability.
• Improve the care of patients exposed to treatable poisonings by:
  o Increasing awareness of the epidemiology of toxic exposures
  o Increasing awareness of treatment options

Biosimilars

GMGS listings: Oncology – Biosimilars; Inflammation and Immunology – Biosimilars

• Support clinicians’ understanding of complex biosimilar concepts in order to facilitate meaningful discussion of these concepts with patients
• Support the prudent (safe and effective) use of biologic drugs by
  o Increasing awareness of the regulatory framework governing the approval and prescription of biosimilar drugs
  o Increasing awareness of the FDA purple book

Cardiovascular Metabolic Risk

Cardiovascular Risk Reduction

GMGS listings: CVM - blood pressure/hypertension; CVM - cholesterol/hypercholesterolemia; CVM - diabetes; CVM - overweight or physical activity; CVM - General/Non-Specific

Increase the identification and effective treatment of patients with multiple risk factors for cardiovascular disease and stroke (e.g. hypertension, dyslipidemia, obesity, diabetes) by improving the understanding and clinical practice of healthcare professionals across the globe.

Smoking Cessation

GMGS listing: Smoking Cessation/Tobacco Dependence Treatment

Increase the number of patients who stop smoking by improving the frequency and effectiveness of smoking cessation intervention, including treatment, counseling and support, by healthcare providers.

Questions? Email GlobalMedicalGrants@pfizer.com
Revised March 2019
Inflammatory Skin Diseases

**Atopic Dermatitis**
*GMGS listing: Atopic Dermatitis*
Improve the care of patients manifesting atopic dermatitis (AD) by increasing healthcare provider knowledge of the disease state or unmet need and the emerging strategies for treatment of AD.

**Inflammatory Diseases such as Alopecia and Vitiligo**
*GMGS listings: Alopecia Areata; Vitiligo*
For dermatologists and all healthcare professionals involved in the care and treatment of patients suffering from dermatologic conditions such as alopecia and vitiligo, increase the awareness and understanding of the latest emerging research, ongoing clinical trials, and mechanisms-of-action of new medicines for the treatment of dermatologic conditions.

**Psoriatic Arthritis**
*GMGS listing: Psoriatic Arthritis*
- Improve the care of patients with psoriatic arthritis by increasing healthcare provider knowledge of: (1) the pathophysiology of psoriatic arthritis, (2) the co-management of psoriatic arthritis, (3) the unmet needs in treatment of psoriatic arthritis, and (4) the mechanism of action and clinical data regarding advanced therapies.
- Educate regarding the national and international guidelines for psoriatic arthritis

**Duchenne Muscular Dystrophy**
*GMGS listing: Duchenne Muscular Dystrophy*
Close knowledge gaps regarding the progression of the pathophysiology and clinical manifestations.

**Friedreich’s Ataxia**
*GMGS listing: Friedreich’s Ataxia*
Improve the understanding of the progression of the pathophysiology and clinical manifestations.

**Gene Therapy**
*GMGS listing: Gene Therapy*
Close knowledge gaps regarding gene therapy applications and clinical development and conduct of clinical trials.

*Questions? Email GlobalMedicalGrants@pfizer.com*
Revised March 2019
Growth Hormone Deficiency

*GMGS listing: Endocrine - Growth Hormone Deficiency*

Improve the knowledge base of health care providers, educators, and third party payers working in the area of GHD.

Hemophilia

*GMGS listing: Hemophilia*

Facilitate enhanced coordination of care and communications between patients with clotting or bleeding disorders, including hemophilia, and their doctors, and ensure practitioners know how to safely treat and monitor these patients.

Infectious Disease

**Clostridium difficile**

*GMGS listing: Infectious Disease- Clostridium difficile*

- Increase the understanding of the burden of Clostridium difficile infection.
- Increase awareness of ongoing research of preventative vaccines for Clostridium difficile infection

**Respiratory Syncytial Virus (RSV)**

*GMGS listing: Infectious Disease-RSV*

- Increase understanding of burden of disease of RSV in infants, children and adults
- Increase understanding of immune response to RSV in infants, children and adults
- Increase awareness of ongoing research of preventative vaccines for RSV

**Group B Streptococcus (GBS)**

*GMGS listing: Infectious Disease- GroupB Strep*

- Increase understanding of burden of disease of GBS in adults
- Increase understanding of immunological biomarkers for GBS infection in infants and adults
- Increase awareness of ongoing research of preventative vaccines for GBS

**Inflammatory bowel disease (IBD)**

*GMGS listings: Inflammatory Bowel Disease (IBD); Ulcerative Colitis*

Improve the care of patients with inflammatory bowel disease (IBD) by increasing healthcare provider knowledge of the emerging strategies for treatment of IBD.

*Questions? Email GlobalMedicalGrants@pfizer.com*

Revised March 2019
Lysosomal Storage Diseases

*GMGS listing: Lysosomal Storage Diseases*

Improve positive outcomes in patients with Lysosomal Storage Diseases by facilitating enhanced coordination of care and communication between multidisciplinary teams of healthcare professionals, ensuring practitioners know how to safely treat and monitor patients.

Metabolic Conditions

**Non-Alcoholic Steatohepatitis (NASH)**

*GMGS listing: CVM - Non-Alcoholic Steatohepatitis (NASH);*

The goals are to accelerate innovations in the diagnosis and treatment of NASH, and to improve evidence-based NASH education for health care providers.

**Myotonic Dystrophy (DM1)**

*GMGS listing: Myotonic Dystrophy (DM1)*

Improve the understanding of the progression of the pathophysiology and clinical manifestations.

Oncology

**Acute Lymphoblastic Leukemia (ALL)**

*GMGS listing: Oncology – Hematologic*

For hematologists, oncologists, transplant physicians, and all healthcare professionals involved in the care and treatment of patients with ALL, increase the awareness and understanding of the latest emerging research, ongoing clinical trials, and the potential use of novel targeted agents for the treatment of ALL.

Questions? Email GlobalMedicalGrants@pfizer.com

Revised March 2019
Acute Myeloid Leukemia (AML)  
**GMGS listing: Oncology - Hematologic** 
For hematologists, oncologists, transplant physicians, and all healthcare professionals involved in the care and treatment of patients with AML, increase the awareness and understanding of the latest emerging research, ongoing clinical trials, and the potential use of novel targeted agents for the treatment of AML, either alone or in combination with chemotherapy.

Breast Cancer  
**GMGS listing: Oncology - Breast** 
For oncologists and all healthcare professionals involved in the care and treatment of patients with advanced or metastatic breast cancer, increase the awareness and understanding of the latest emerging research, ongoing clinical trials, and mechanisms-of-action of new medicines in particular advances in CDK 4/6 inhibition and PARP inhibition. Other topics of interest include optimizing clinical practice, understanding patient experiences and implementation of clinical pathways.

Chronic Myelogenous Leukemia (CML)  
**GMGS listing: Oncology - Hematologic** 
For hematologists, oncologists and all healthcare professionals involved in the care and treatment of patients with CML, increase awareness of the importance of long term safety with BCR-ABL TKI treatment, improve ability to select optimal treatment options, and individualize treatment and dosage based on each patient’s medical history and comorbidities (e.g. cardiovascular risk factors.)

Immuno-Oncology (IO)  
**GMGS listing: Oncology - Immuno-Oncology** 
For medical oncologists and all healthcare professionals involved in the care and treatment of patients with lung, bladder, ovarian, renal, gastric, skin, or head & neck cancers:
- Increase understanding of the rationale for novel IO strategies such as anti-PD-1/PD-L1 therapy
- Increase awareness of when immunotherapy should be considered as a treatment option for patients to include selection, sequencing, and combinations
- Improve ability to manage associated IO treatment issues including side effects and progression

Non-Small Cell Lung Cancer (NSCLC)  
**GMGS listing: Oncology – Lung** 
For oncologists, pulmonologists, pathologists, surgeons, interventional radiologists, and all healthcare professionals involved in the care and treatment of patients with NSCLC, increase the awareness and understanding of the importance of treating patients based on the timely results of molecular testing (e.g. ALK, EGFR, ROS1) in order to optimize patient outcomes.

**Questions?** Email [GlobalMedicalGrants@pfizer.com](mailto:GlobalMedicalGrants@pfizer.com)

Revised March 2019
Renal Cell Carcinoma (RCC)
GMGS listing: Oncology – Genitourinary
For oncologists, urologists and all healthcare professionals involved in the care and treatment of patients with advanced RCC, increase awareness of the evolving treatment landscape and clinical trial results, and also improve clinical competence in applying this information to patient care, especially with respect to sequencing, scheduling, dosing, adjuvant use, use of combination therapies, and management of side effects.

General Oncology - Basic Science and Clinical Research Interests
GMGS listing: Oncology - General
Through the academic exchange of research and ideas, enhance the discovery and translation of novel cancer therapies, increase scientific understanding of their mechanisms-of-action as well as the efficacy, safety, and potential clinical applicability. Topics of interest include antiangiogenesis, signal transduction, cytotoxic potentiators, tyrosine kinase inhibitors, checkpoint inhibitors, biosimilars, antibody drug conjugates, biomarkers, and immuno-oncology (IO) specific correlates of safety and efficacy. Also within IO there is particular interest in advancing the understanding of combinations of novel IO therapies with conventional, targeted, radiation, and existing IO therapies.

Pain

Chronic Pain assoc’d w/ Osteoarthritis; Chronic Low Back Pain (Pfizer/Lilly alliance)
GMGS listing: Pain - Osteoarthritis
Please see below under ‘Clinical Areas Reviewed through Joint Alliances/Partnerships.’

Pulmonary Arterial Hypertension (PAH)
GMGS listing: Pulmonary Arterial Hypertension
Improve the understanding of the progression of the pathophysiology and clinical manifestations.

Rheumatoid Arthritis
GMGS listing: Rheumatoid Arthritis
- Improve the care of patients with rheumatoid arthritis (RA) by (1) increasing the knowledge of healthcare providers (HCPs) on the pathophysiology of RA, (2) the unmet needs in the treatment of rheumatoid arthritis, and (3) the mechanism of action and clinical data of current advanced therapies
- Address challenges in the management of patients with RA (such as vaccinations, comorbidities, treat to target, etc)

Questions? Email GlobalMedicalGrants@pfizer.com
Revised March 2019
Sickle Cell

*GMGS listing: Sickle Cell Disease*

Improve healthcare provider’s knowledge of diagnosis and treatment of sickle cell disease and facilitate enhanced coordination of care and communication between patients with sickle cell disease and healthcare providers.

**TTR Amyloidosis (ATTR)**

*GMGS listing: TTR Amyloidosis*

Improve the care of patients by:

- Closing knowledge gaps in disease epidemiology, pathophysiology, diagnosis, and emerging treatment paradigms.
- Addressing barriers to diagnosis and strategies that reduce burdens for patients and providers along the pathway to diagnosis.
- Exploring strategies that empower patients to play an active role in understanding TTR amyloidosis and available diagnostic and treatment options.
- Increasing awareness of the changing epidemiology of TTR amyloidosis with a focus on the prevalence of hereditary ATTR and wild-type ATTR subtypes in the modern era.
- Increasing awareness of at risk and undiagnosed populations with TTR amyloidosis with a focus on improving strategies that facilitate the diagnosis of patients early in the disease course before overt cardiomyopathy has ensued.
- Increasing awareness of bone radiotracer scintigraphy as a non-invasive alternative to invasive endomyocardial biopsy for the diagnosis of TTR cardiac amyloidosis in select patients.
- Supporting the dissemination of information related to the study of emerging treatment options to improve patient important outcomes in TTR amyloidosis.

**Vaccine Preventable Diseases**

Improve immunization across the life span by addressing perceptions of society and healthcare providers related to pediatric, adolescent and adult immunizations.

**Pneumococcal Disease**

*GMGS listing: Vaccine Preventable Disease - Pneumococcal*

Improve the care of pediatric patients by:

- Highlighting the disparity between family physicians and pediatricians in adherence to recommended childhood vaccination schedule.
- Addressing barriers to vaccination and series completion with a focus on lower education and socioeconomic groups and other under-immunized populations including rural and inner city settings as well as barriers to vaccination within the current medical system, including bureaucratic structure issues and HCP availability.

Questions? Email [GlobalMedicalGrants@pfizer.com](mailto:GlobalMedicalGrants@pfizer.com)

Revised March 2019
• Assessing how barriers can be overcome in the current medical system where making changes in the practice is often difficult given the current bureaucratic structure of many practices and the demands on HCP time
• Exploring gaps in the healthcare system that negatively impact the burden of invasive pneumococcal disease and search for ways to minimize these gaps through educational programs

Improve the care of adult patients by
• Increasing the awareness of the changing epidemiology of pneumococcal pneumonia in adults
• Increasing the awareness and understanding of adult pneumococcal vaccination guidelines including the limitations of the guidelines
• Increasing the percentage of adults receiving national guideline and medical society recommended immunizations

Meningococcal Disease
GMGS listing: Vaccine Preventable Disease - Meningococcal
Optimize the prevention of meningococcal disease by:
• Enhancing understanding of changing meningococcal epidemiology including mortality, morbidity and long term consequences of meningococcal disease
• Increasing awareness of the risk of meningococcal disease for all ages
• Improving meningococcal vaccine recommendation implementation and vaccine uptake including:
  o Risk of meningococcal disease by healthcare practitioners
  o Improving access to meningococcal vaccines
  o Understanding the preferences and choices of parents and adolescents towards meningococcal vaccines and disease prevention

Women’s Health
GMGS listing: Women’s Health/Menopause
Support education where concepts, issues and advances in women’s reproductive and/or post-reproductive health care are discussed with a goal of improving individual and population health outcomes. Areas of particular interest include (but are not limited to) an individualized approach to the management of menopause and a women’s health continuum of care across the lifespan.

Support for the Global CME/CE/CPD Profession and Under-represented Healthcare Professionals
GMGS listing: Support for the Professions
This category supports live, MAJOR national and regional conferences whose target audience includes professionals who work in, develop, implement and/or support CME/CE/CPD and QI for healthcare professionals; and live, MAJOR conferences of societies whose members include under-represented or minority healthcare professionals. NOTE: If an organization requests and receives funding through the IGLC grants portal, they are no longer eligible for funding directly from a Pfizer Country Office, or regional office.

Questions? Email GlobalMedicalGrants@pfizer.com
Revised March 2019
Clinical Areas Reviewed through Joint Alliances/Partnerships

Please note, in order to apply to any of the Joint Alliance/Partnership programs listed below your organization must also meet Pfizer’s eligibility requirements. Click here to view further details about eligibility.

Chronic Pain Associated with Osteoarthritis and Chronic Low Back Pain
Pfizer and Lilly are working together on grants in support of medical education in chronic pain associated with osteoarthritis and chronic low back pain. We are committed to supporting innovative, independent medical education for healthcare professionals. All grant applications should be submitted to Pfizer only, to avoid application duplication. To apply now, go to our grant management system.

Diabetes Treatment
Pfizer and Merck are working together on grants in support of diabetes treatment-related education. The goal of this education is to increase the understanding of SGLT2 inhibition in the management of diabetes.

All grant applications should be submitted to Merck only. Please refer to the Merck website for information.

Nonsteroidal Anti-Androgen Treatment of Prostate
Pfizer and Astellas are working together on grants in support of prostate cancer-related education. The goal of this education is to increase the ability of healthcare professionals to consistently provide their patients with optimal guidelines-based care.

All grant applications should be submitted to Astellas only. Please refer to the Astellas website for information.

Thrombosis Prevention / Anti-coagulation
Pfizer and Bristol Myers Squibb (BMS) are working together on grants in support of thrombosis / anticoagulation-related education. The goal of this education is to decrease the unmet medical needs in the prevention and treatment of venous and arterial thrombosis.

All grant applications should be submitted to Bristol Myers Squibb only. Please refer to the Bristol Myers Squibb website for information.

Questions? Email GlobalMedicalGrants@pfizer.com
Revised March 2019